A Phase II Study of Tesetaxel in Subjects Previously Treated With Chemotherapy for Metastatic Transitional Cell Carcinoma of the Urothelium.

Trial Profile

A Phase II Study of Tesetaxel in Subjects Previously Treated With Chemotherapy for Metastatic Transitional Cell Carcinoma of the Urothelium.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Tesetaxel (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Sponsors Genta (CEASED)
  • Most Recent Events

    • 04 Nov 2011 Planned number of patients changed from 27 to 33 as reported by ClinicalTrials.gov.
    • 28 Oct 2010 New source identified and integrated (Memorial Sloan-Kettering Cancer Center).
    • 05 Oct 2010 Planned end date (December 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top